About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
PETX - Aratana Therapeutics| Previous Close | $4.92 | Open | |
| Volume | Market Cap | ||
| Yield | Last Dividend |
| Week 21 Breakout Forecast: Short-Term Pi... | 05/18/19 |
| No summary available. | |
| Week 20 Breakout Forecast: Short-Term Pi... | 05/13/19 |
| No summary available. | |
| Aratana (PETX) Reports Q1 Loss, Tops Rev... | 05/08/19 |
| Aratana (PETX) delivered earnings and revenue surprises of -40.00% and 5.51%, respectively, for the quarter ended March 2019. Do the numbers hold clue... | |
| Aratana Therapeutics misses by $0.03, be... | 05/08/19 |
| No summary available. | |
| Week 19 Breakout Forecast: Short-Term Pi... | 05/06/19 |
| No summary available. | |
| Aratana (PETX) May Report Negative Earni... | 05/01/19 |
| Aratana (PETX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with t... | |
| Elanco Animal Health And Aratana Therape... | 04/29/19 |
| Last Friday, Elanco announced the acquisition of Aratana Therapeutics and shareholders of Aratana will receive Elanco shares instead. Elanco is adding... | |
| Biotech News Recap: Portola Gains Approv... | 04/29/19 |
| No summary available. | |
| Week 18 Breakout Forecast: Short-Term Pi... | 04/28/19 |
| No summary available. | |
| This Biotech Is Going to the Dogs | 04/27/19 |
| Elanco Animal Health said it would acquire Aratana Therapeutics, a biotech that develops dog and cat medicine, in a stock deal valued at about $234 mi... | |
| INTC, RGEN, BGG and HELE among midday mo... | 04/26/19 |
| No summary available. | |
| Elanco Animal Health Announces $245M Sto... | 04/26/19 |
| Elanco Animal Health Inc (NYSE: ELAN ) announced Friday that it has struck a deal to buy pet therapeutics company Aratana Therapeutics Inc (NASDAQ: PE... | |
| Aratana Therapeutics and Repligen among ... | 04/26/19 |
| No summary available. | |
| Earnings movers dominate premarket gaine... | 04/26/19 |
| Aratana Therapeutics (PETX) +37% on Elanco takeover. Regional Health Properties (RHE) +20%. Reebonz Holding (RBZ) +17%. Highpower (HPJ) +14% on receiv... | |
| Animal health giant Elanco to acquire Ar... | 04/26/19 |
| Shares of Aratana Therapeutics shot up 39% in premarket trade on Friday after Elanco Animal Health announced it would be acquiring the pet therapeutic... | |
| Aratana up 32% premarket on Elanco takeo... | 04/26/19 |
| Elanco Animal Health (ELAN) has agreed to acquire Aratana Therapeutics (PETX), a developer of treatments for dogs and cats, for an undisclosed sum. On... | |
| Week 15 Breakout Forecast: Short-Term Pi... | 04/06/19 |
| No summary available. | |
| Aratana Therapeutics (PETX) Presents At ... | 03/14/19 |
| No summary available. | |
| Aratana Therapeutics (PETX) Presents At ... | 03/13/19 |
| No summary available. | |
| Aratana Therapeutics, Inc. (PETX) CEO Cr... | 03/12/19 |
| No summary available. | |
| Aratana Therapeutics misses on revenue | 03/12/19 |
| No summary available. | |
| New finance chief at Aratana Therapeutic... | 02/04/19 |
| No summary available. | |
| Aratana Therapeutics: A Dog Eat Dog Worl... | 01/25/19 |
| No summary available. | |
| 2 Biotech Stocks On Watch Early In The W... | 01/22/19 |
| No summary available. | |
| 2 Biotech Stocks On Watch Early In The W... | 01/22/19 |
| No summary available. | |
| New CEO at Aratana Therapeutics | 01/18/19 |
| No summary available. | |
| New CEO at Aratana Therapeutics | 01/18/19 |
| No summary available. | |
| Biotech Forum: What To Watch In The Week... | 01/14/19 |
| No summary available. | |
| Biotech Forum: What To Watch In The Week... | 01/14/19 |
| No summary available. | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Swing Trading Cheap Stocks <~ $10 | Michael S. DeVries | 66.00 % | Follow |
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
